Sugi Predict

Sugi Predict / Compounds / SCHEMBL496759

SCHEMBL496759

SCHEMBL496759

O=C(O)c1cn2ccsc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.43
▸ TP53 P04637 6/20 0.43
▸ NPC1 O15118 5/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ TSHR P16473 4/20 0.43
▸ HPGD P15428 4/20 0.43
▸ MAPT P10636 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CYP19A1 P11511 1/20 0.43
▸ HSD17B10 Q99714 3/20 0.42
▸ NFKB1 P19838 2/20 0.42
▸ NFKB2 Q00653 2/20 0.42
▸ RELA Q04206 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ KMT2A Q03164 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL570167 0.98 PTGS1 (0.46) PTGS1PTGS2SMN1; SMN2TP53NPC1
SCHEMBL4423753 0.83 TP53 (0.43) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL17454368 0.83 TP53 (0.49) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL10766644 0.79 SMN1; SMN2 (0.47) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL17452625 0.79 TP53 (0.45) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL13352171 0.79 GAA (0.48) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL2815932 0.79 MAPT (0.53) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL1572425 0.75 ALDH1A1 (0.55) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL11315876 0.73 TSHR (0.60) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL7054988 0.72 TP53 (0.63) SMN1; SMN2TP53NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115418686-B Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2023-01-10 — — CN claimed
CN-115418686-A Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2022-12-02 — — CN claimed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 — — EP claimed
EP-2155739-B1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-06 — — EP claimed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 — — US claimed
EP-2185512-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-05-19 — — EP claimed
EP-2155739-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-02-24 — — EP claimed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 — — WO claimed
WO-2008139416-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-11-20 — — WO claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 — — EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 — — US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO claimed
CN-119707927-A Triazole-containing compound, synthesis method and application thereof 贵州大学 2025-03-28 — — CN disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 — — US disclosed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 — — US disclosed
US-7229480-B2 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof THE PROCTER & GAMBLE COMPANY (US) 2007-06-12 — — US disclosed
US-7229480-B2 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof THE PROCTER & GAMBLE COMPANY (US) 2007-06-12 — — US disclosed
US-20060211747-A1 Methods of screening for compounds which inhibit the activity of Cdc34 in a zinc-mediated manner and compounds obtained by this method FURET PASCAL 2006-09-21 — — US disclosed
US-4794120-A BACTERICIDES, FUNGICIDES SYNTHELABO (FR) 1988-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 PTGS1 145/4885PTGS2 128/4885SMN1; SMN2 2963/4885
US-20060211747-A1 Methods of screening for compounds which inhibit the activity of Cdc34 in a zinc-mediated manner and compounds obtained by this method CDC45, CDC37, CDC5L PTGS1 3930/4885PTGS2 4139/4885SMN1; SMN2 3162/4885
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 PTGS1 145/4885PTGS2 128/4885SMN1; SMN2 2963/4885
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R PTGS1 940/4885PTGS2 929/4885SMN1; SMN2 3038/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 PTGS1 1317/4885PTGS2 1395/4885SMN1; SMN2 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.